{
    "Trade/Device Name(s)": [
        "Atellica\u00ae CH Enzymatic Creatinine_3 (ECre3)"
    ],
    "Submitter Information": "Siemens Healthcare Diagnostics Inc.",
    "510(k) Number": "K212223",
    "Predicate Device Reference 510(k) Number(s)": [
        "K070727"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "JFY"
    ],
    "Summary Letter Date": "July 15, 2021",
    "Summary Letter Received Date": "July 16, 2021",
    "Submission Date": "July 15, 2021",
    "Regulation Number(s)": [
        "21 CFR 862.1225"
    ],
    "Regulation Name(s)": [
        "Creatinine Test System"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Creatinine"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma (lithium heparin)",
        "Plasma (dipotassium EDTA)",
        "Urine"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Atellica\u00ae CH Analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Enzymatic assay"
    ],
    "Methodologies": [
        "Coupled enzymatic reactions"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for the Atellica CH Enzymatic Creatinine_3 (ECre3) assay for quantitative creatinine measurement in serum, plasma, and urine using the Atellica CH Analyzer.",
    "Indications for Use Summary": "For in vitro quantitative determination of creatinine in human serum, plasma (lithium heparin and dipotassium EDTA), and urine to aid in diagnosis and treatment of renal diseases and monitoring of renal dialysis.",
    "fda_folder": "Clinical Chemistry"
}